Jump to content
Powered by
  • BIOPRO BW
  • Healthcare industry
  • Bioeconomy

Healthcare industry

Main navigation

  • Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close
  • Databases

    Databases

    Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Funding

    JOINT TRANSNATIONAL CALL 2021

    Funding programme, Funded by: Horizon 2020, Submission deadline: 04/03/2021
    https://www.gesundheitsindustrie-bw.de/en/database/funding/joint-transnational-call-2021
  • Stem cell therapy for regenerating intervertebral discs - 16/07/2020 800_Wisi_Focus_Web.jpg

    Ulm’s simulator has Europe’s back

    Back pain is often caused by intervertebral disc disorders. Much has already been tried and is available to help patients. Despite extensive progress, there is still no surefire recipe for success. iPSpine, an EU-funded project to which researchers from Ulm are contributing interdisciplinary engineering and biomedical expertise, aims to design a novel therapy for back pain based on intervertebral disc regeneration.

    https://www.gesundheitsindustrie-bw.de/en/article/news/Ulms-simulator-has-europes-back
  • Translational oncology - 26/05/2020 NCT_181204_3435.jpg

    Translation: driver of cancer medicine

    The fight against cancer is a pressing issue. Although technological advances in the treatment, prevention and early detection of cancer have improved over the past few decades, the number of people affected is increasing. Cancer medicine now wants to counteract this by joining forces with other players involved in the field.

    https://www.gesundheitsindustrie-bw.de/en/article/news/translation-driver-cancer-medicine
  • Company profile - 16/12/2019 Ausschnitt aus dem Mikrofluidik-System von Velabs, das dicht gepackt ist mit einzelnen Tröpfchen

    Velabs Therapeutics GmbH: each droplet is a test system

    Using microfluidics to detect new therapeutic antibodies is, in simple terms, the concept developed by Velabs Therapeutics GmbH. The Heidelberg-based start-up was spun out from the European Molecular Biology Laboratory (EMBL) in 2017 with the support of EMBLEM Technology Transfer GmbH. More recently, investors have provided the young company with additional funding to expand its technologies and applications.

    https://www.gesundheitsindustrie-bw.de/en/article/news/velabs-therapeutics-gmbh-each-droplet-test-system
  • Article - 08/11/2019 Qiu_Bild_1.jpg

    Nanorobots as future minimally invasive tools for the eye

    It is difficult to place drugs in the right place in the eye. When using droplets, only a small fraction of the drug reaches its target. Injecting drugs into the eye is also more a matter of luck than judgement. Basic researchers at the Max Planck Institute for Intelligent Systems Stuttgart have developed a nanorobot that can be loaded with active ingredients for treating eye diseases and directed through the solid tissue of the vitreous body.

    https://www.gesundheitsindustrie-bw.de/en/article/news/Nanorobots-future-minimally-invasive-tools-for-eye
  • Vision Zero in oncology - 02/09/2019 Titelcover_Vision-Zero.jpg

    Call for a comprehensive master plan for preventing and treating cancer

    While a cancer-free world may seem unrealistic given the increasing numbers of cancer cases, we need to reach a social consensus that cancer deaths are unacceptable and that everything possible must be done to prevent them. Leading cancer researchers around the world are calling for more investment in prevention research and cancer screening to move towards the vision of a near cancer-free world.

    https://www.gesundheitsindustrie-bw.de/en/article/news/call-for-comprehensive-master-plan-preventing-treating-cancer
  • Article - 05/03/2019 Schematic showing EBV particles in a blood vessel.

    Vaccination against oncogenic Epstein-Barr viruses

    Almost all humans are infected with Epstein-Barr viruses (EBV), which are linked to the development of benign diseases such as infectious mononucleosis as well as several cancers. Scientists from the German Cancer Research Center have developed a new strategy for creating a vaccine that targets different EBV virus life phases and has the potential to provide effective protection against EBV infection.

    https://www.gesundheitsindustrie-bw.de/en/article/news/vaccination-against-oncogenic-epstein-barr-viruses
  • Expert interview - 08/08/2018 Das Bild zeigt das Brustbild des ALS-Forschers, und Ärztlichen Direktors der Neurologischen Klinik der Uni Ulm, Prof. Albert Ludolph. Der Neurologe ist Sprecher des DZNE-Standorts Ulm.

    Ludolph: diagnosing and treating neurodegenerative disorders

    Ulm has long been a world leader in diagnosing and treating rare neurological disorders, notably amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD) and Huntington's disease (HD). We spoke with Professor Albert C. Ludolph, spokesperson for the Ulm DZNE site, medical director of the Clinic for Neurology at the RKU (University and Rehabilitation Clinics of Ulm) and world-renowned ALS researcher.

    https://www.gesundheitsindustrie-bw.de/en/article/news/ludolph-diagnosing-and-treating-neurodegenerative-disorders
  • Article - 05/04/2018 Translational cancer research is able to bridge the valley of death. The drawing shows a bridge spanning the two valleys of death in medical research - one between preclinical and clinical research and another between the clinical efficacy of drugs as demonstrated by clinical trials and the evidence of real benefits for patients and society.

    Crossing the valley of death with translational cancer research

    It can take many decades before promising research results become therapies that have a positive effect on cancer patients. Most research projects go adrift somewhere between the laboratory and the bedside in the so-called "valley of death". Projects carried out at the DKFZ show that translational cancer research actually works.

    https://www.gesundheitsindustrie-bw.de/en/article/news/crossing-the-valley-of-death-with-translational-cancer-research
  • Press release - 21/02/2018 Michael Baumann, Chairman and Scientific Director of the German Cancer Research Center (DKFZ) in Heidelberg, receives the 2017 German Cancer Award in the category "Translational Research".

    German Cancer Award for Michael Baumann

    Michael Baumann, Chairman and Scientific Director of the German Cancer Research Center (DKFZ) in Heidelberg, receives the 2017 German Cancer Award in the category "Translational Research". The science award, which is sponsored by the German Cancer Society and the German Cancer Foundation, is one of the most prestigious distinctions in cancer medicine in Germany.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/german-cancer-award-for-michael-baumann
  • Guest article - 22/09/2014 22076_de.jpg

    Experience report: Six months Shanghai

    Sebastian Giese, a doctoral student at the University of Freiburg, spent six months in Shanghai with funding from a Baden-Württemberg Ministry of Science, Research and the Arts China scholarship. Below, Sebastian tells us about his impressions of the country and its people and his experiences in the megacity.

    https://www.gesundheitsindustrie-bw.de/en/article/news/experience-report-six-months-shanghai
  • Article - 19/05/2014 21459_de.jpg

    Alcoholism: the molecular basis of addiction and deprivation

    Scientists at the Central Institute of Mental Health in Mannheim use rats and mice to study the genetic basis and neurobiological mechanisms of alcohol addiction, the changes that occur during alcohol deprivation and the factors that favour a relapse. In translational research, the results from animal experiments are reviewed using alcohol-dependent patients in order to turn them quickly into preventive strategies and therapies.

    https://www.gesundheitsindustrie-bw.de/en/article/news/alcoholism-the-molecular-basis-of-addiction-and-deprivation
  • Press release - 15/01/2014 20872_de.jpg

    Hit Discovery Constance GmbH: a new hub for HTS and compound management

    Hit Discovery Constance GmbH (“HDC”), a new joint venture organisation between Lead Discovery Center (Dortmund/Germany), Centre for Drug Design and Discovery (CD3, KULeuven, Leuven/Belgium) and Axxam (Milan/Italy) has started its operation. The new company is based in Constance (Germany) and will make use of the already established equipment and know-how of the former Takeda/Nycomed/Altana screening and compound management facilities at the site.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/hit-discovery-constance-gmbh-a-new-hub-for-hts-and-compound-management
  • Article - 18/11/2013 20653_de.jpg

    The HAE Accelerator – "compete to speed up your start-up"

    The HAE Accelerator is an international programme involving biomedical clusters in Cambridge (UK), Leuven (Belgium) and Heidelberg (Germany) that seeks to identify, train and put innovative start-up teams in the three countries in contact with international VC investors. Of the three business ideas that were awarded a HAE Investors’ Choice Award in September 2013, InoCard from Heidelberg came first with a new gene therapy for myocardial…

    https://www.gesundheitsindustrie-bw.de/en/article/news/the-hae-accelerator-compete-to-speed-up-your-start-up
  • Article - 09/09/2013 Official opening of the French-German Week of the Sciences in the Elysée Palace by German Federal Research Minister Johann Wanka (on the left) and the French Science Minister Geneviève Fioraso (right) in Paris on 15th April 2013.<br /> <br />

    The Heinrich-Lanz Centre for Personalised Medicine in Mannheim

    A Centre for Translational Research and Personalised Medicine is currently emerging at the Faculty of Medicine in Mannheim, University of Heidelberg. The new centre is expected to boost the development of new therapies in cooperation with partners from Germany and abroad. The centre also works closely with the “French-German Advanced Translational Drug Discovery Center”, a unique, large-scale, cross-border research cooperation between French and…

    https://www.gesundheitsindustrie-bw.de/en/article/news/the-heinrich-lanz-centre-for-personalised-medicine-in-mannheim
  • Article - 12/11/2012 18578_de.jpg

    Otmar D. Wiestler – combining excellent research and cancer medicine

    The University of Tübingen Medical Faculty’s award of an honorary doctorate to the Chairman of the Executive Board of the German Cancer Research Center, Professor Dr. Otmar D. Wiestler, was not just a distinction awarded to a renowned neuropathologist, oncologist and stem cell researcher, it also honoured a well-known personality who has made a significant contribution to shaping health research in Germany.

    https://www.gesundheitsindustrie-bw.de/en/article/news/otmar-d-wiestler-combining-excellent-research-and-cancer-medicine
  • Article - 09/01/2012 16136_de.jpg

    Nutritional medicine: Can certain foods help treat cancer?

    Researchers at the Centre for Nutritional Medicine (ZEM), a joint institution of the Universities of Hohenheim and Tübingen, are investigating whether and to what extent certain food components can support the treatment of cancer and are hoping to derive scientifically founded dietary recommendations from their findings.

    https://www.gesundheitsindustrie-bw.de/en/article/news/nutritional-medicine-can-certain-foods-help-treat-cancer
  • Article - 19/12/2011 16051_de.jpg

    Gundram Jung – a pioneer in antibody-mediated cancer immunotherapy

    Physicist, medical doctor, researcher and now also a founder of a company – Professor Dr. Gundram Jung’s career has never gone in a completely straight line although his goal has always been the same: to develop innovative immunotherapies for the treatment of cancer. Jung’s genetically modified antitumour antibodies are now close to clinical application.

    https://www.gesundheitsindustrie-bw.de/en/article/news/gundram-jung-a-pioneer-in-antibody-mediated-cancer-immunotherapy
  • Article - 12/09/2011 15319_de.jpg

    TransLimm brings new immunotherapies to patients more rapidly

    With the establishment of the Center for Translational Immunology TransLimm the University of Tübingen has initiated a network whose objective is to quickly and effectively transfer innovative therapies into clinical application. Patients suffering from acute leukaemia might soon benefit from therapies involving antibodies optimized by recombinant antibody technology.

    https://www.gesundheitsindustrie-bw.de/en/article/news/translimm-brings-new-immunotherapies-to-patients-more-rapidly
  • Press release - 27/06/2011 14614_de.jpg

    NMI TT GmbH – creating value from research

    NMI TT GmbH is a subsidiary of the NMI Natural and Medical Sciences Institute in Reutlingen with which it works closely. Developments by the renowned NMI are commercialised by NMI TT GmbH and the profit flows back into the NMI’s research activities – thus leading to a value creation cycle that benefits research and development as well as the economy.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/nmi-tt-gmbh-creating-value-from-research
  • Article - 30/05/2011 The new building of the National Center for Tumour Diseases on the campus of Heidelberg University Hospital <br />

    From bench to bedside to bench

    The term translational medicine does not always refer to the concept “from bench to bedside and back”, and indeed is often used to refer to many other, somewhat distant, concepts. However, the new translation centres and translational research consortia do correspond to the original meaning. These new centres and consortia have become effective structures in health research in Germany whose goal is the continuous improvement of the diagnostic and…

    https://www.gesundheitsindustrie-bw.de/en/article/news/from-bench-to-bedside-to-bench
  • Dossier - 30/05/2011 13541_de.jpg

    Knowledge and technology transfer as a social responsibility

    Technology transfer that efficiently exploits the intellectual property created by publicly funded research is necessary in order to turn scientific discoveries into successful innovations that improve people’s quality of life and boost the economy. The efforts made to rapidly transfer research results from the laboratory into clinical application for the benefit of patients leads to new strategic partnerships and structures in the field of…

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/knowledge-and-technology-transfer-as-a-social-responsibility
  • Article - 06/03/2011 13837_de.jpg

    Heidelberg Translational Lung Research Centre

    University and non-university research institutions in Heidelberg that carry out research into lung diseases have established an expert network – the Heidelberg Translational Lung Research Centre – which is part of the new BMBF-funded German Centre for Lung Research. In Heidelberg, research focuses on the development and treatment of cystic fibrosis, chronic obstructive pulmonary diseases and lung cancer.

    https://www.gesundheitsindustrie-bw.de/en/article/news/heidelberg-translational-lung-research-centre
  • Press release - 10/02/2011

    Blood-clotting protein linked to cancer and septicaemia

    Scientists at the EMBL and the University of Heidelberg have shown how stressed cells boost the production of the blood-clotting protein thrombin and how cancer cells may be taking advantage of this process. This research could lead to new therapies.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/blood-clotting-protein-linked-to-cancer-and-septicaemia
  • Article - 03/12/2010 The photo shows Dr. Bernd Dallmann welcoming the audience to the Science meets Business Day in the Freiburg Concert Hall.

    Review: Science meets Business Day 2010 (part I)

    Germinating seeds biosensors in the human body deaf people learning to hear again and new approaches to combat the flu virus the lectures held at the Science meets Business Day which concluded this years BioValley Science Week once again highlighted the innovations brought about through the joint efforts of research and industrial players on the Upper Rhine.

    https://www.gesundheitsindustrie-bw.de/en/article/news/review-science-meets-business-day-2010-part-i

Page 1 / 2

sb_search.block.search_result.other.pages

  • 1
  • 2
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • Telemedicine BW
    • MDR & IVDR
  • Portals
    • BIOPRO BW
    • Healthcare industry
    • Bioeconomy
  • To top

stay informed

Subscribe to newsletter

Social Media

  • Xing
  • Twitter
  • LinkedIn
  • Rss
  • Privacy statement
  • Legal notice
  • Sitemap
  • Contact
© 2021
Website address: https://www.gesundheitsindustrie-bw.de/en/search